MORGAN FINK: Open Payments
NPI 1437635190 · NEWARK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,973 in 104 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $120 · 2025 $1,973
Food & beverage: $1,894Education: $79
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 20 | $745 |
| ABBVIE INC. | 25 | $286 |
| EVOKE PHARMA, INC. | 11 | $192 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Ardelyx, Inc. | 4 | $64 |
| Braintree Laboratories, Inc. | 3 | $56 |
| Madrigal Pharmaceuticals | 3 | $53 |
| Celltrion USA Inc. | 3 | $47 |
| Ferring Pharmaceuticals Inc. | 2 | $44 |
Products named: TREMFYA, GIMOTI, XIFAXAN, RINVOQ, ENTYVIO, SKYRIZI, IBSRELA, SUFLAVE.
Industry payments across NJ — which companies pay providers there.
